|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||77.26 - 78.53|
|52-week range||76.45 - 106.66|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||14.71|
|Earnings date||28 Oct 2022|
|Forward dividend & yield||3.33 (4.23%)|
|Ex-dividend date||06 May 2022|
|1y target est||106.58|
The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trialsAbout 75,000 adults in the U.S. living with prurigo nodularis are most in need of new treatment options Approval represents the second dermatology indication for Dupixent and fifth disease indication overall in the U.S. Paris and Tarrytown, N.Y. September 28, 2022